Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure

European Journal of Heart Failure

Volumn 8, Issue 8, 2006, Pages 804-809

  Trikas, Athanasios ^a   Antoniades, Charalambos ^a   Latsios, Giorgos ^a   Vasiliadou, Karmen ^a   Karamitros, Ioannis ^a   Tousoulis, Dimitris ^a   Tentolouris, Costantinos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; Heart failure; Inflammatory process; Levosimendan

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEVOSIMENDAN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FAILURE; HEMODYNAMICS; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIGENS, CD95; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INFLAMMATION; INFUSIONS, PARENTERAL; INTERLEUKIN-6; MALE; PYRIDAZINES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SOLUBILITY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751190290     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.03.003     Document Type: Article

References (31)

1. Kivikko M., Antila S., Eha J., Lehtonen L., and Pentikainen P. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42 (2002) 43-51
2. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., and Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98 (1998) 2141-2147
3. Kaheinen P., Pollesello P., Levijoki J., and Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43 (2004) 555-561
4. Ng T.M. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy 24 (2004) 1366-1384
5. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study: a randomized double-blind trial). Lancet 360 (2002) 196-202
6. Cleland J.G., Nikitin N., and Gowan J.M. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc Ther 2 (2004) 9-19
7. Parissis J.T., Adamopoulos S., Antoniades C., et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 (2004) 1309-1312
8. + channel in rat arterial myocytes. J Pharmacol Exp Ther 283 (1997) 375-383
9. Sundberg S., Antila S., Scheinin H., et al. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 36 (1998) 629-635
10. Antila S., Pesonen U., Lehtonen L., et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 23 (2004) 213-222
11. Adamopoulos S., Parissis J., and Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 (2001) 517-526
12. Hasper H., Hummel M., Kleber F.X., Reindl, and IVolk H.D. Systemic inflammation in patients with heart failure. Eur Heart J 19 (1998) 761-765
13. Anker S., Egerer K.R., Volk H.D., et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79 (1997) 1426-1430
14. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842
15. Peschel T., Schonauer M., Thiele H., Anker S., Schuler G., and Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 5 (2003) 609-614
16. Conraads V.M., Jorens P.G., De Clerck L.S., et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 6 (2004) 483-491
17. Ceconi C., Curello S., Bachetti T., Corti A., and Ferrari R. Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium?. Prog Cardiovasc Dis 48 (1998) 25-30
18. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the mammalian heart. J Clin Invest 92 (1993) 2303-2312
19. Krown K.A., Page M.T., Nguyen C., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. J Clin Invest 98 (1996) 2854-2865
20. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92 (1995) 1487-1493
21. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 7 (1996) 231-240
22. Higuchi Y., McTiernan C.F., Frye C.B., et al. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 9 (2004) 1892-1897
23. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
24. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
25. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
26. Jankowska E.A., von Haehling S., Czarny A., et al. Activation of the NF-[kappa]B system in peripheral blood leukocytes from patients with chronic heart failure. Eur J Heart Fail 7 (2005) 984
27. Narula J., Pandey P., Arbustini E., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335 (1996) 1182-1189
28. Nishigaki K., Minatoguchi S., Seishima M., et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29 (1997) 1214-1220
29. Yamagouchi S., Yamaoka M., Okuyama M., et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 83 (1999) 1500-1503
30. Sliwa K., Skudicky D., Bergemman A., et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 35 (2000) 701-705
31. Genth-Zotz S, von Haehling S, Bolger AP, et al. The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure. Eur J Heart Fail in Press (article online Dec. 2, 2005).